Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9601486 | Clinical Oncology | 2005 | 5 Pages |
Abstract
Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder (TCC) improves survival. This is one of the most important developments in the management of muscle-invasive bladder cancer in recent times. There is an improved absolute 5-year survival of at least 5% for T2-T4 disease. To achieve this benefit, a cisplatin-containing combination is required. There is no difference in survival whether radical radiotherapy or radical cystectomy is given as subsequent definitive treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.B. McLaren,